Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
Daiichi Sankyo
Harvard Business School
Federal Trade Commission
Express Scripts

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,143,277

« Back to Dashboard

Summary for Patent: 6,143,277

Title: Metered dose inhaler for salmeterol
Abstract:A metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising salmeterol, or a salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents and one or more excipients.
Inventor(s): Ashurst; Ian C. (Ware, GB), Herman; Craig S. (Raleigh, NC), Li; Li (Scotch Plains, NJ), Riebe; Michael T. (Raleigh, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC) Glaxo Group Limited (Greenford, GB)
Application Number:08/770,533
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Device; Use; Composition;

No matches for this query

International Patent Family for Patent: 6,143,277

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2217954► Subscribe
European Patent Office1908488► Subscribe
Estonia9700374► Subscribe
Germany69630111► Subscribe
Germany69634865► Subscribe
Denmark0820323► Subscribe
Eurasian Patent Organization000892► Subscribe
Czech Republic9703260► Subscribe
Canada2467462► Subscribe
China1186447► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Argus Health
US Department of Justice
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus